



Published in final edited form as:

Nature. 2019 November ; 575(7783): 540–544. doi:10.1038/s41586-019-1753-7.

Structures of a RAG-like transposase during cut-and-paste transposition

Chang Liu^{1,4}, Yang Yang^{2,3,4}, David G. Schatz^{1,*}

¹Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.

²Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.

³Howard Hughes Medical Institute, Yale University, New Haven, CT, USA.

⁴These authors contributed equally

Summary

Transposons have played a pivotal role in genome evolution¹ and are believed to be the evolutionary progenitors of the RAG1-RAG2 recombinase², an essential component of the adaptive immune system in jawed vertebrates³. Here we report one crystal and five cryo-electron microscopy structures of a RAG1-like transposase, HzTransib^{4,5}, that capture the entire transposition process from the apo enzyme to the terminal strand transfer complex with transposon ends covalently joined to target DNA, at resolutions of 3.0–4.6 Å. These structures reveal a butterfly-shaped complex that undergoes two cycles of dramatic conformational changes in which the “wings” of the transposase unfurl to bind substrate DNA, close to execute cleavage, open to release the flanking DNA, and close again to capture and attack target DNA. HzTransib possesses unique structural elements that compensate for the absence of a RAG2 partner including a loop that interacts with the transposition target site and an accordion-like C-terminal tail that elongates and contracts to help control the opening and closing of the enzyme and assembly of the active site. Our findings reveal the reaction pathway of a eukaryotic cut-and-paste transposase in unprecedented detail and illuminate some of the earliest steps in the evolution of the RAG recombinase.

Keywords

RAG; V(D)J recombination; Transib; DNA transposition; strand transfer; evolution; X-ray crystallography; cryo-electron microscopy

Reprints and permissions information is available at <http://www.nature.com/reprints>. Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*Correspondence and requests for materials should be addressed to david.schatz@yale.edu.

Author Contributions

C.L. and D.G.S. conceived the project and designed the experiments. C.L. performed cloning, protein expression, purification, complex reconstitution, sample screening using negative-stain electron microscopy, cryo-EM grids preparation and functional assays. C.L. and Y.Y. carried out protein crystallization, crystal structure determination, cryo-EM data collection and processing, atomic model building and refinement. C.L. and D.G.S. analyzed data and wrote the manuscript with input from Y.Y.

Competing interests

The authors declare no competing interests.

Transposons are present in all kingdoms of life and move within or between genomes using transposon-encoded transposases⁶. Many DNA transposases and retroviral integrases contain a conserved RNase H-like domain that uses three acidic residues (the DDE/D motif) to coordinate magnesium and catalyze DNA cleavage and integration⁷. The RAG1-RAG2 recombinase (RAG), which shares this RNase H catalytic domain⁸, generates DNA double-strand breaks at recombination signal sequences (RSSs) to initiate V(D)J recombination in developing lymphocytes of jawed vertebrates^{3,9}. The RAG1 catalytic core and RSSs are thought to have evolved from the transposase and terminal inverted repeats (TIRs), respectively, of an ancient *Transib* transposon¹⁰. Acquisition of a *RAG2-like* gene by a *Transib* element is proposed to have generated a “RAG transposon” that subsequently played a key role in the evolution of *RAG1-RAG2* loci and V(D)J recombination². Unlike cut-and-paste transposition, which is an excision-and-integration reaction, V(D)J recombination is an excision-and-end joining reaction that rejoins the ends of the excised segment to protect the genome against hazardous insertions (Fig. 1a). Hence, RAG has been subject to different evolutionary constraints than its transposase ancestors, particularly in the events that occur after DNA cleavage.

Transib from *Helicoverpa zea* (*HzTransib*) is an active transposon whose TIR resembles a portion of the RSS (Fig. 1b)⁴ and whose transposase (*HzTransib*) cleaves DNA by a nick-hairpin mechanism like that of RAG and the hAT family transposase Hermes^{5,11} (Fig. 1a). *HzTransib*⁵, Hermes¹², and RAG^{13,14} are active *in vitro* for the subsequent strand transfer reaction that completes transposition but for RAG, this step is strongly suppressed *in vivo*².

Recent advances in RAG structural biology have illuminated the molecular basis for RSS recognition and cleavage^{8,15–17}. However, transposition mediated by DDE/D family enzymes that proceed via hairpinning is less well understood, particularly at the final step of integration into target DNA. In contrast to the availability of structures capturing the strand transfer complexes of bacteriophage Mu¹⁸ and retroviral integrases^{19–22}, transposon integration has been visualized structurally for only one eukaryotic DNA transposase, Mos1^{23,24}, and Mos1 employs a catalytic mechanism that does not involve a hairpin intermediate²⁵. As the only known active *Transib* transposase, *HzTransib* provides a unique opportunity for analysis of a RAG2-independent RAG1-family protein and for comparative insights into the impact of RAG2 on RAG1 function and RAG evolution.

Here we describe near-atomic resolution crystal or cryo-electron microscopy (cryo-EM) structures of *HzTransib* in the Apo form and complexed with intact TIR substrate, nicked TIR substrate, cleaved transposon ends, and transposon ends covalently joined to target DNA (Extended Data Fig. 1–4, Extended Data Table 1, 2). An additional complex, with *HzTransib* bound to transposon ends and target DNA prior to strand transfer, was also observed in and modeled from the cryo-EM data. These structures represent the most complete structural description to date of a eukaryotic cut-and-paste transposition reaction, explain the target site sequence preferences of RAG-family transposases, and reveal the conformational changes that enable the same catalytic center to perform both transposon excision and integration.

Opening of HzTransib upon TIR engagement

Apo HzTransib exhibits a modular domain arrangement similar to that of RAG1⁸ (Fig. 1c, d). The N-terminal dimerization and DNA-binding domain (DDBD) serves as the dimerization interface and is connected by an extended pre-RNase H (PreR) loop to a split RNase H-like (RNH) domain containing three conserved catalytic carboxylates⁵ (D125, D224, and E435), all of which are required for activity⁵ (Extended Data Fig. 1c, d). E435 is separated from the rest of RNH by two zinc-binding domains, ZnC₂ and ZnH₂ (collectively, ZnB), which form a C₂H₂ zinc finger (Extended Data Fig. 5a), as in RAG1⁸. The following C-terminal domain (CTD) folds back to interact with DDBD, and the protein ends with a ~30 amino acid C-terminal tail (CTT) made up of three short helices that bridge from DDBD to ZnB. The absence of a nonamer-binding domain (NBD) (Extended Data Fig. 5b) is consistent with the observation that HzTransib TIRs have sequence similarity to the heptamer but not the nonamer of the RSS (Fig. 1b)^{4,26}.

Despite low (16.4%) sequence identity between HzTransib and RAG1 core, individual domains from the two proteins are readily superimposable (Extended Data Fig. 5a), providing support for the model that Transib and RAG1 are evolutionarily related. These alignments also reveal several differences between HzTransib and RAG1, three of which (red boxes in Extended Data Fig. 5a) are extended structural elements in RAG1, absent from HzTransib, that together constitute a substantial portion of the RAG2-binding interface in RAG1 (Extended Data Fig. 5c). These three missing elements explain the absence of a RAG2-like entity in *HzTransib* and poor RAG2 binding by HzTransib *in vitro*^{4,26}.

Binding of intact TIR substrate to form the pre-reaction complex (PRC) induces a dramatic relocation of the ZnB domains, from being tightly packed components of the enzyme core to lateral extensions that jut away from the core (Fig. 2a, Extended Data Fig. 6a and Supplementary Video 1). This 49° rotation and 26 Å centroid movement of ZnB exposes the TIR-binding grooves (Extended Data Fig. 6a) and is twice as large as the RAG1 ZnB domain movement that occurs upon intact RSS binding¹⁶. Viewed from the front, the HzTransib PRC resembles a butterfly with wings spread and DNA as antennae, with ZnB domain rotation constituting an “unfurling” of the wings, one from the back and one from the front of the butterfly (Fig. 2a, Extended Data Fig. 6a).

The HzTransib PRC adopts a *trans* architecture in which each TIR engages the active site of one HzTransib (the *cis* subunit) but is bound primarily by the other HzTransib (the *trans* subunit) (Fig. 2b), as for RAG and other DDE transposases and retroviral integrases^{7,15,16}. CTT from the *cis* subunit tracks through the heptamer major groove and interacts with the backbone of TIR position 3 (Extended Data Fig. 6b). *Trans* DNA binding interactions include base-specific interactions between CTD and TIR positions 5–7 and between DDBD and the phosphate backbone at TIR positions 8–13 (Extended Data Fig. 6c, d). No interaction is observed beyond position 13, and consistent with this, serial 3' truncations of the TIR demonstrate that cleavage *in vitro* is robust with only the first 13 bp of the TIR (Extended Data Fig. 1e).

The PRC is a cleavage-incompetent complex in which the scissile phosphate for nicking is far from the active site and E435 is not positioned for catalysis (Extended Data Fig. 6e). This indicates that a substantial structural alteration will be required before nicking of the NTS could take place.

HzTransib closure accompanies catalysis

Incubation of HzTransib with nicked TIR substrate at 30°C in Ca²⁺ yielded a complex that is poised for hairpin formation, referred to as the hairpin-forming complex (HFC). The HFC is more compact than the PRC, with the ZnB domains having undergone a major 51° inward rotation along an axis nearly perpendicular to that of the original outward movement (Fig. 2c, Extended Data Fig. 6g and Supplementary Video 1). The inward folding of the ZnB “wings” has been accompanied by several other changes in the complex. First, flanking DNA has rotated ~180° and tilted ~30° toward the *cis* ZnB domain, with bases C1 and A-1* becoming flipped out of the helix (Fig. 2d and Extended Data Fig. 6h–j). A similar DNA rotation is seen in RAG-nicked RSS structures^{15,16}. Second, a ~6 Å movement of E435 has led to full assembly of the active site (Extended Data Fig. 6k). And third, HFC formation results in numerous new *cis* HzTransib-DNA contacts. The first 3 bp of the heptamer make extensive base-specific interactions with α10 and α16 of the *cis* subunit (Extended Data Fig. 6h) and the extrahelical C1 base is buried in a pocket formed by α10, α12 and a loop of CTT (Extended Data Fig. 6i). ZnB enfolds the flanking DNA (Fig. 2c) and interacts with the first 7 bp of flanking DNA; in the PRC, such interactions extended only to position –4 (Extended Data Fig. 6l, m). Due to its lack of a RAG2 subunit, interactions of HzTransib with flanking DNA are much less extensive than for RAG, where RAG2 contacts extend to position –15 in the PRC and HFC^{15,16}.

HzTransib reopens upon DNA cleavage

The HzTransib transposon end complex (TEC) structure, in which hairpin formation and release of flanking DNA has occurred, provides a unique view of post-cleavage events for hAT/RAG family enzymes. Release of the flanking DNA hairpin ends is associated with a 26° rotation of the ZnB domains that partially spreads the “wings” of the complex (Fig. 2e, Extended Data Fig. 6n and Supplementary Video 1). C1 of the heptamer has now switched from its flipped-out position to base pair with G1* and transposon end DNA has become largely superimposable with that in the PRC (Extended Data Fig. 6o). In the absence of flanking DNA, the ZnB domains are able to tilt and interact with the exposed heptamer ends, physically sequestering them through interactions involving N322, R343 and K350 (Fig. 2f). The 3'-OH that will be the nucleophile for the target integration reaction is not in close proximity to the three active site carboxylates (Fig. 2f), indicating that substantial distortions of the transposon end and conformational changes in HzTransib will be necessary for the strand transfer reaction.

The TEC structure illustrates how HzTransib prepares for target capture and reveals several structural differences with RAG and other transposases. The substantial outward rotation of ZnB seen in the TEC exposes the DNA binding groove and likely facilitates flanking DNA release and target capture. No such movement is seen for RAG or Hermes^{12,15}. In addition,

HzTransib's interactions with the cleaved transposon ends might shield the DNA from DNA repair enzymes and inhibit end joining. Similar interactions with the cleaved RSS ends are not seen in the RAG signal end complex (SEC)¹⁵, a difference that might reflect the different evolutionary constraints faced by HzTransib and RAG. Finally, dislocation of the 3'-OH nucleophile out of the HzTransib active site in the TEC is not observed in the RAG SEC or TEC of other transposases^{12,15,23,27}.

Target DNA capture and strand transfer

During transposition, hairpin formation and flanking DNA release are followed by non-covalent capture of target DNA to form the target capture complex (TCC) and then by the strand transfer reaction that covalently joins the transposon ends to target DNA to form the strand transfer complex (STC). The HzTransib TCC and STC were formed through cleavage of intact TIR substrates without the provision of a specific target DNA. One 3D class of HzTransib-TIR complexes contained clearly resolved density connecting the catalytic centers of the two HzTransib subunits (Extended Data Fig. 7a), which was determined (see Methods) to be the 5 bp target site generated after attack of the transposon ends at a 5'-CGGTG-3' sequence in an additional TIR substrate molecule (Fig. 3a).

The STC structure reveals that engagement of target DNA triggers active site reassembly driven by rotational closure of the ZnB domains, which now enfold target DNA in much the same manner that they previously bound flanking DNA in the HFC (Fig. 3b, Extended Data Fig. 7b, and Supplementary Video 1). The $\alpha 9$ - $\alpha 10$ loop has moved downward toward the RNH domain (Fig. 3c) and interacts extensively with target site DNA (Fig. 3d). Target site DNA exhibits sharp ($\sim 75^\circ$) bends one bp from each end, resulting in a $\sim 150^\circ$ overall directional change (Fig. 3b and Extended Data Fig. 7c). V328 fills the gaps left by the breaks in base stacking on the continuous strands, stabilizing the highly kinked DNA conformation (Fig. 3d).

HzTransib exhibits a 5'-CGNCG-3' transposition target site consensus sequence and target sites almost always contain a 5'-YR-3' dinucleotide step at one or both ends (Fig. 3e and Supplementary Table 1). This preference is likely due to the inherent deformability and reduced base-stacking of a pyrimidine-purine step²⁸. Notably, HzTransib's GC-rich target site DNA remains fully base-paired in the STC despite its highly distorted duplex structure.

A trifurcation of density observed at the transposon end-target DNA junction suggested that the cryo-EM map represented a mixture of HzTransib in complex with target DNA before (TCC) and after (STC) transposon end integration (Extended Data Fig. 7d). Indeed, calculation of the difference map between the cryo-EM reconstruction and the STC model suggested that a portion of the particles contain uncleaved target DNA (Extended Data Fig. 7e) and allowed modeling of intact target DNA in the cryo-EM density. In this TCC model, the active site captures two Mg^{2+} ions (Fig. 3f), while none are observed in the disassembled active site of the TEC (Fig. 2f). One non-bridging oxygen is hydrogen bonded with H274 (Fig. 3f). This histidine, which is conserved in several eukaryotic transposase superfamilies^{29,30}, has been proposed to be a key component of a DDHE/D (as opposed to DDE/D) enzyme active site³⁰, and our data are consistent with this proposal. The distances

separating the scissile phosphate and the attacking oxygen and the two metal ions in the TCC model strongly argue that the active site could catalyze the strand transfer reaction³¹ (Extended Data Fig. 7f).

CTT helps drive HzTransib domain closure

During HzTransib's two cycles of opening and closing, CTT acts as an accordion-like element that extends and refolds in concert with the unfurling and furling of HzTransib's "wings" (Fig. 4a, b and Supplementary Video 1). In apo-HzTransib, CTT is a compact bundle of three short helices, $\alpha 18$ – $\alpha 20$ (Fig. 4b). $\alpha 20$ is anchored through interactions to $\alpha 12$ and $\alpha 13$ of ZnB and stays almost static relative to ZnB throughout the transposition cycle (Extended Data Fig. 8a, b). In contrast, $\alpha 18$ and $\alpha 19$ drastically alter their secondary structures during the structural gymnastics of HzTransib. The large rotation of ZnB that accompanies binding of intact TIR DNA dramatically elongates and deforms $\alpha 18$ and $\alpha 19$ (Fig. 4a, b). This CTT coil might help drive the inward movement of ZnB and closure of the HzTransib dimer in the subsequent PRC to HFC transition, during which $\alpha 18$ reforms (Fig. 4a, b). $\alpha 18$ becomes deformed again during HzTransib opening and flanking DNA release in the TEC and then reforms during HzTransib closure and target DNA engagement in the STC (Fig. 4a, b). $\alpha 18$ is particularly well conserved across Transib proteins and the hydrophobic residues that anchor $\alpha 20$ to ZnB also exhibit sequence conservation (Extended Data Fig. 8e). Hence, CTT is likely an ancient and functionally conserved component of many Transib transposases, and its deletion from HzTransib almost abolished DNA cleavage activity (Extended Data Fig. 8c).

The C-terminal tails of jawed vertebrate RAG1 and invertebrate RAG1-like (RAG1L) proteins, including the BbRAG1L subunit of the ProtoRAG transposase from amphioxus³², show sequence similarity only with $\alpha 18$ of HzTransib CTT (Extended Data Fig. 8e) and are unlikely to perform functions similar to that of CTT. The RAG1 C-terminal tail is dispensable for activity, and the functionally-important BbRAG1L C-terminal tail interacts with TIR DNA downstream of the heptamer and not with ZnB, and shares no structural similarity with HzTransib CTT³³ (Extended Data Fig. 8d). Hence, the CTT module of RAG1 family proteins has apparently been readily adapted during evolution to address different functional imperatives.

RAG2 acquisition and transposase evolution

The lack of structural information for Transib has made it difficult to explore the structural and functional implications of the acquisition of a RAG2-like subunit by RAG1 early in evolution. The absence of RAG2 is likely of particular relevance for the large domain excursions that characterize the HzTransib transposition reaction (Fig. 4a). The ZnB outward rotation that accompanies initial DNA binding in the PRC provides extensive access to DNA binding surfaces, thereby helping to compensate for the lack of stabilizing RAG2-flanking DNA interactions^{15,16}. The subsequent dramatic domain closure that yields the HzTransib HFC creates ZnB-flanking DNA interactions (Extended Data Fig. 6m) that are contributed predominantly by RAG2 in the RAG HFC^{15,16}. Inter-dimer interactions mediated by RAG2

stabilize the closed configuration of the RAG HFC¹⁵ and their absence might help explain the need for a unique CTT to help drive inward rotation during HzTransib HFC formation.

Perhaps most strikingly, the $\alpha 9$ - $\alpha 10$ target site-interaction loop of HzTransib (Fig. 3c, d), a nearly ubiquitous feature of predicted Transib proteins, is lacking in RAG1 and invertebrate RAG1-like proteins predicted to have a RAG2-like partner (Fig. 3g). By stabilizing target DNA in the TCC and STC, the HzTransib target site interaction loop likely compensates for the absence of stabilizing RAG2-DNA interactions. We propose that acquisition of a *RAG2-like* gene by a *Transib* transposon to give rise to the first RAG1/RAG2 transposon² set in motion two linked evolutionary processes in RAG1: acquisition of new RAG2 binding interfaces (Extended Data Fig. 5a and 7g) and loss of the target site interaction loop, which was now no longer needed for stabilization of target DNA.

The structure of the HzTransib STC reveals distinctive structural and mechanistic features of cut-and-paste transposition. The large overall target DNA distortion created by the deep binding pocket of HzTransib contrasts with the relatively mild target DNA bend and flat target DNA binding groove in retroviral integrases^{19–22} (Extended Data Fig. 7c). A second distinctive feature of HzTransib is the large protein conformational change that occurs during target DNA capture (Fig. 4a and Supplementary Video 1). In contrast, Mos1^{23,24} and retroviral integrases^{19,21,34} adopt very similar structures before and after target DNA capture. Finally, the HzTransib STC structure helps explain multiple features of RAG-family transposition: the preferred 5 bp target site duplication length, GC-rich target sites^{5,10,13,32}, target site hotspot sequence preferences^{13,35}, and the ability of mismatches and other DNA distortions to stimulate transposition by RAG^{35,36}.

Methods

No statistical methods were used to predetermine sample size. The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment.

Cloning of HzTransib transposase and substrates.

The full length or an N-terminal truncated fragment (residues 17–507) of HzTransib transposase fused to a C-terminal His₆ tag or an N-terminal maltose-binding protein (MBP) tag were cloned into pFastBac1 expression vector (ThermoFisher Scientific) between BamHI and HindIII restrictive sites. pB-5'/3'TIR, a derivative of pBR322 containing the TIR substrate for ProtoRAG transposases, was described previously³³. To generate TIR substrate for HzTransib transposases, the ProtoRAG 5'TIR and 3'TIR of pB-5'/3'TIR were substituted by the first 51 bp and 50 bp of HzTransib transposon 5'TIR and 3'TIR, respectively, using In-Fusion cloning (Clontech). The PCR amplified and linearized HzTransib substrate contains a HzTransib 5'TIR and 3'TIR separated by 411 bp between their tips, 126 bp of DNA flanking 5'TIR and 276 bp of DNA flanking 3'TIR. The whole substrate was depleted of 5'-CAC-3' sequence instances except for those contained in 5'TIR and 3'TIR regions.

Protein expression and purification.

MBP- or His₆-tagged HzTransib transposase was expressed in Sf9 insect cells using the Bac-to-Bac Baculovirus Expression System according to the manufacturer's protocol (ThermoFisher Scientific). Cells expression His₆-tagged HzTransib transposase were re-suspended in lysis buffer (20 mM Tris-HCl, pH7.5, 500 mM NaCl, 1 mM dithiothreitol (DTT)) and lysed by six passes through an Emulsiflex C3 homogenizer (Avestin). Cell lysate was cleared by centrifugation at 40,000 r.p.m (~146,000 x g) using a Type 50.2 Ti rotor (Beckman Coulter) for 1 h at 4 °C and was mixed with pre-equilibrated Ni-NTA Agarose resin (Qiagen) for 2 h with continual rotation. The resin was loaded onto a gravity flow column, washed with 5x column volume (CV) of lysis buffer and protein eluted with 5x CV of elution buffer (20 mM Tris-HCl, pH7.5, 200 mM NaCl, 20 mM Imidazole, 1 mM DTT). The elute was further purified and buffer exchanged using a Superdex 200 Increase 10/300 GL size-exclusion chromatography column (GE Healthcare) in 20 mM Tris-HCl, pH 7.5, 200 mM NaCl and 1 mM Tris(2-carboxyethyl) phosphine hydrochloride (TCEP-HCl). Cells expression MBP-tagged HzTransib transposase were re-suspended in lysis buffer (20 mM Tris-HCl, pH7.5, 500 mM NaCl, 1 mM DTT) and purified using amylose resin (New England BioLabs) in 20 mM Tris-HCl, pH7.5, 200 mM NaCl, 1 mM DTT, followed by size-exclusion chromatography purification in 20 mM Tris-HCl, pH 7.5, 200 mM NaCl and 1 mM TCEP. Both forms of HzTransib protein are a dimer in solution and an active TIR-dependent nuclease (Extended Data Fig. 1).

Mutant HzTransib proteins with active site residue mutations or C-terminal tail (CTT) truncation (removal of residues 478–507) were fused to MBP tag and purified in the same way as MBP-tagged wild-type HzTransib transposase.

His₆-tagged human HMGB1 with C-terminal truncation (residues 1–165) was expressed in *E.coli* BL21 (DE3) and purified as previously described¹⁵.

Sf9 cells were obtained from Thermo Fisher Scientific. Cells lines used were not authenticated or tested for mycoplasma contamination.

Crystallization and data collection.

Purified His₆-tagged HzTransib transposase was concentrated to ~6.3 mg/ml and used in crystallization screening. HzTransib crystals were grown by sitting-drop vapor diffusion at 20°C in 100 mM HEPES, pH 7.0, 0.7–0.8 M NaH₂PO₄ and 0.75 M KH₂PO₄. Crystals were cryo-protected in crystallization solution supplemented with 17.5% glycerol and flash frozen in liquid nitrogen. Heavy atom derivatives of HzTransib crystals were prepared by soaking crystals in cryo-protection solution supplemented with 1 M NaBr for 2–5 min, 0.5 M NaI for 2–5 min, 2.5 mM K₂OsCl₆ for 2 h, 2.5 mM K₂PtCl₄ for 2 h, or 2.5 mM ethylmercury thiosalicylate (EMTS) for 2h. Data were collected at 100 K at beamline 24ID-E and 24ID-C of the Advanced Photon Source (APS) at Argonne National Laboratory. The dataset of the native crystal was collected at 0.9792 Å. The datasets for Br-, I-, Os-, Pt- and Hg-derivative crystals were collected at 0.9197 Å, 1.4586 Å, 1.1398 Å, 1.0718 Å and 1.0087 Å, respectively. All X-ray diffraction data were indexed, integrated and scaled with the XDS package³⁷ (Extended Data Table 1).

Crystal structure determination and refinement.

Phases were determined with native crystal dataset and five heavy atom-derivative datasets by multiple isomorphous replacement with anomalous scattering (MIRAS) method. Heavy atom sites were identified using SHELXD³⁸ and the structure was determined using AutoSol³⁹. The initial model was built automatically using AutoBuild⁴⁰ of PHENIX software package and manually rebuilt in COOT⁴¹. The model was refined in PHENIX⁴² with non-crystallographic symmetry (NCS) restraints. The final structure was refined to 3.0 Å with R_{work} and R_{free} of 22.0% and 27.7%, respectively. Due to poor electron densities, residues 17–20, 235–238, 247–264 and 502–507 were not included in the final model. The structure was validated with MolProbity⁴³. 92.98% of residues are in the favoured regions of the Ramachandran plot, 6.47% in additional allowed regions, and 0.56% in the disallowed region.

HzTransib-TIR complex assembly.

24 bp intact TIR substrate was generated by annealing equimolar amounts of two complementary oligonucleotides: 5'-CTAGATCTCACGGTGGATCGAAAA-3' and 5'-TTTTCGATCCACCGTG*AGATCTAG-3' (heptamer sequence is underlined. * indicates a phosphorothioate bond introduced between the two nucleotide residues). 32 bp intact TIR substrate was generated by annealing equimolar amounts of the two oligonucleotides: 5'-GATCTGGCCTAGATCTCACGGTGGATCGAAAA-3' and 5'-TTTTCGATCCACCGTGAGATCTAGGCCAGATC-3'. 32 bp nicked TIR substrate was generated by annealing equimolar amounts of the following three oligonucleotides: 5'-GATCTGGCCTAGATCT-3', 5'-CACGGTGGATCGAAAA-3' and 5'-TTTTCGATCCACCGTGAGATCTAGGCCAGATC-3' (a phosphorothioate bond was introduced between the heptamer and flanking DNA on transferred strand for the nicked TIR substrates used in HzTransib-TIR complex reconstitution in the presence of Mg^{2+}). To reconstitute the HzTransib-intact TIR complex, purified MBP-tagged HzTransib was mixed with 24 bp intact TIR substrate and HMGB1 in a 1:2:2 molar ratio in the presence of Mg^{2+} at 4°C for 1 h, followed by size-exclusion chromatography purification in 20 mM Tris-HCl, pH 7.5, 50 mM KCl, 10 mM MgCl_2 , 1 mM TCEP. HzTransib-nicked TIR complex was reconstituted by mixing MBP-tagged HzTransib, 32 bp nicked TIR substrate and HMGB1 in a 1:2:2 molar ratio in the presence of Mg^{2+} at 4°C or in the presence of Ca^{2+} at 30°C for 1 h, followed by size-exclusion chromatography purification. Catalytically active HzTransib-TIR complex was reconstituted by mixing MBP-tagged HzTransib with 32 bp intact TIR substrate and HMGB1 in a 1:2:2 molar ratio in the presence of Mg^{2+} , and was allowed to react at 30°C for 50 min before being frozen on cryo-EM grids.

Cryo-EM sample preparation and data acquisition.

Purified HzTransib-TIR complex (3.5 µl at ~1.2 µM) was applied to freshly glow-discharged Quantifoil 300 mesh or 200 mesh holey carbon grids with R 1.2/1.3 hole pattern (Electron Microscopy Sciences). Grids were blotted for 5.5 s under 100% humidity and plunge-frozen in liquid nitrogen-cooled liquid ethane using a Vitrobot Mark IV (ThermoFisher Scientific). Cryo-EM datasets were collected on a Titan Krios G2 electron microscope (Yale University) operated at 300 kV equipped with a GIF Quantum LS imaging filter (Gatan, Inc.) and a K2

summit direct electron detector (Gatan, Inc.) in super-resolution mode. The image stacks were collected at a nominal magnification of 130,000x, corresponding to 0.525 Å per super-resolution pixel, at a dose rate of 7.0–7.5 e⁻/physical pixel/s. The total exposure time for each movie was 8 s, thus leading to a total accumulated dose of 50.8–54.4 e⁻/Å², which was fractionated into 40 frames. All movies were recorded with a defocus ranging from –1.5 to –2.5 µm. The statistics of cryo-EM data acquisition are summarized in Extended Data Table 2.

Image processing.

Dose-fractionated super-resolution movies were binned over 2×2 pixels, yielding a pixel size of 1.05 Å, then subjected to motion correction and dose-weighting using MotionCorr²⁴⁴. The non-dose-weighted aligned images were used for contrast transfer function estimation by CTFFIND-4.1.10⁴⁵. The dose-weighted images were used for autopicking, classification and reconstruction. For HzTransib-TIR complex datasets, roughly 40,000 particles were automatically picked using a Laplacian-of-Gaussian blob detection in RELION-3.0⁴⁶, followed by a round of 2D classification to generate templates for a new round of autopicking. The newly autopicked particles were subjected to multiple rounds of 2D classification in RELION-3.0 to remove junk particles. Particles in good 2D classes were extracted for initial model generation in RELION-3.0. The initial model was low-pass filtered to 50 Å to serve as a starting reference for 3D auto-refinement in RELION-3.0 using all particles in good 2D classes. The signal corresponding to MBP regions was then subtract, followed by 3D classification with a mask encompassing the HzTransib transposases dimer plus TIRs DNA region. Good 3D classes were selected and iteratively refined to yield high-resolution maps in RELION-3.0 with either C1 or C2 symmetry. To improve the map quality and interpretability of the HzTransib ZnB domains in HzTransib-TIR PRC, the particles from good 3D class(es) were symmetry-expanded and subjected to masked 3D classification with residual signal subtraction focusing on the HzTransib ZnB domain using a previously published procedure⁴⁷. All refinements followed the gold-standard procedure, in which two half datasets were refined independently. The overall resolution was estimated based on the Fourier shell correlation (FSC) cutoff at 0.143 between the two half-maps, after a soft mask was applied to mask out solvent region. The final maps were sharpened within RELION-3.0. Local resolution variation was estimated from the two half-maps using ResMap⁴⁸.

Cryo-EM model building and refinement.

The crystal structure of HzTransib dimer was rigid-fitted into the HzTransib-TIR complexes cryo-EM maps in UCSF Chimera⁴⁹. Due to large domain movements, the HzTransib ZnB domains were fitted separately from the other part of the structural model. The DNA fragments corresponding to heptamer plus the first 16 bp of coding flank from RAG-RSS PRC (PDB 6CIK) or HFC (PDB 5ZE0) structures were first fitted into HzTransib PRC or HFC cryo-EM map, respectively, and mutated to the input TIR sequence in COOT. The complex resulting from incubation of HzTransib with nicked TIR substrate at 4°C in the presence of Mg²⁺ adopted a catalytically incompetent conformation very similar to that of the HzTransib-intact TIR complex (Extended Data Fig. 6f). This complex is referred to as the PRC with nicked TIRs. For HzTransib STC structure, the modeling and sequence registers of the target DNA are based on the following observations. (1) The well-defined

cryo-EM density for the target site suggests a 5'-YRRYR-3' motif (Y stands for pyrimidine, R stands for purine) (Extended Data Fig. 7a), 5'-CGGTG-3' is the only match throughout the entire sequence of the input TIR substrate DNA. (2) HzTransib prefers GC-rich target site for integration. *In vitro* transposition has shown that HzTransib can mediate transposon integration at target sites with an exact 5'-CGGTG-3' sequence (Supplementary Table 1). (3) Reconstruction of HzTransib STC cryo-EM map without imposing C2 symmetry shows asymmetric DNA helix density at two flanking DNA-binding regions in the HzTransib dimer. The cryo-EM density for two flanking site DNA helices exhibits a 7–9 bp difference in length, which coincides with 18-bp and 9-bp flanking DNA on two sides of the 5'-CGGTG-3' sequence in our TIR DNA substrate. By contrast, reconstructing the cryo-EM map of other HzTransib-TIR complexes without C2 symmetry results in a map with nearly perfect two-fold symmetry. (4) The sequence registers for target DNA in this model is also largely supported by the cryo-EM density features. The structural models were manually adjusted and rebuilt in COOT and refined using PHENIX real-space refinement with secondary structure restraints, rotamer restraints, Ramachandran restraints and NCS constraints (except for HzTransib-TIR STC, in which no NCS was applied). The final structures were validated with MolProbity. The final HFC and STC structures contain amino acid residues 21–500 of HzTransib and most TIR DNA nucleotides, except for the two most distal base-pairs of the transposon end-flanking DNA and 5' end of target DNA. In PRC structures, residues 17–20, 131–141, 245–252 of HzTransib and the most distal base-pair of the transposon end-flanking DNA are not modeled due to poor density. The TEC model contains all 16 bp of transposon end DNA. HzTransib residues 17–20, 136–141, 245–265 are disordered and are not included in the final TEC model. No HMGB1 density was seen in any of the cryo-EM density maps, and thus was not included in the cryo-EM atomic models. All molecular representations were generated in UCSF Chimera and UCSF ChimeraX⁵⁰. Sequence alignments were performed in Clustal Omega⁵¹ and displayed using the online server of Esript 3.0⁵².

***In vitro* DNA cleavage assay.**

Linear substrate DNA used in the cleavage experiments was generated by PCR using the pBR322-based vectors as template and purified by agarose gel electrophoresis. Wild-type or mutant HzTransib (300 nM final concentration), substrate DNA (final concentration 30 nM) were incubated in reaction buffer (25 mM MOPS, pH7.0, 50 mM KCl, 2 mM DTT, 5 mM MgCl₂; 16 µl final reaction volume) at 30°C for 1 h. Reactions were stopped by adding 1.25 µl 2.5% SDS, 5 µl proteinase K (200 µg/ml) and 2 µl 0.5 M EDTA followed by incubation at 55°C for 3 h. Samples were briefly centrifuged and the supernatant mixed with 6 µl 5x high density TBE sample buffer (ThermoFisher Scientific) and loaded on a non-denaturing 1x Tris-borate-EDTA (TBE) buffered polyacrylamide gel (Bio-Rad or ThermoFisher Scientific). After 35 min electrophoresis at 160V, gels were stained with SYBR gold (ThermoFisher Scientific) in 1xTBE buffer for 1 h and imaged using a PharosFX Plus (Bio-Rad).

***In vitro* transposition assay.**


Linear donor DNA with tetracycline-resistant gene was amplified by PCR using the pBR322-based vector as template and purified by agarose gel electrophoresis. 0.05 pmol

donor DNA and 0.1 pmol pECFP-1 target plasmid were mixed with 150 ng wild-type HzTransib protein in reaction buffer (25 mM MOPS, pH7.0, 50 mM KCl, 2 mM DTT, 5 mM MgCl₂) and incubated at 30°C for 1 h. After protease K digestion, DNA was ethanol-precipitated. 200 ng of DNA was transformed into electrocompetent MC1061 bacterial cells that were spread onto plates containing kanamycin or kanamycin + tetracycline + streptomycin (KTS)¹³. Plasmids from 54 colonies from KTS plates were sequenced to determine the integration location on the plasmid and target-site duplication (TSD) sequence. Sequence logo representing nucleotide frequencies of HzTransib TSD were generated and visualized with *kpLogo* web server⁵³.

Data availability

Atomic coordinates of six HzTransib or HzTransib-TIR DNA complex structures have been deposited in PDB under accession number 6PQN (HzTransib Apo), 6PQR (HzTransib-intact TIR PRC), 6PQU (HzTransib-nicked TIR PRC), 6PQX (HzTransib-TIR HFC), 6PQY (HzTransib-TIR TEC) and 6PR5 (HzTransib-TIR STC). Five cryo-EM density maps of HzTransib complexed with different TIR DNA have been deposited in the Electron Microscopy Data Bank under accession number EMD-20452, EMD-20453, EMD-20455, EMD-20456, EMD-20457, respectively.


Extended Data



Extended Data Fig. 1. Biochemical characterization of HzTransib transposase and single-particle cryo-EM analysis of HzTransib in complex with intact TIR substrates.

a, Size-exclusion chromatography-multiple angle light scattering (SEC-MALS) analysis of purified HzTransib protein, indicating that it forms a dimer in solution. Size-exclusion chromatography was repeated three times and similar profiles were obtained. MALS experiment was not repeated. **b**, Numbering and sequence of endogenous left end (5'TIR) and right end (3'TIR) of the *HzTransib* transposon with nucleotide differences in black boxes. The first 16 bp of the TIR sequence are the same as the 16 bp transposon end of the

TIR substrates used in structure determination. **c**, Schematic of the TIR substrate DNA used in the in vitro DNA cleavage assay. 5'TIR and 3'TIR are shown as yellow and purple triangles, respectively. **d**, Cleavage of DNA substrates bearing one or two TIRs by MBP-tagged wild-type or mutant HzTransib transposases, each with the N-terminal 16 amino acids removed. The experiment was repeated three times and similar results were obtained. For gel source data, see Supplementary Figure 1. **e**, Cleavage of DNA substrates bearing either full length (lanes 1 and 2) or truncated (lanes 3–8) 5'TIR or 3'TIR, with site of truncation indicated in the substrate name. The experiment was repeated three times and similar results were obtained. Open and closed arrowheads indicate single 5'TIR and single 3'TIR cleavage products, respectively. Red asterisk marks the double cleavage band. The DNA cleavage products were resolved in 5% Tris-borate-EDTA (TBE) polyacrylamide gels and stained with SYBR Gold. **f**, Flowchart of cryo-EM structure determination of HzTransib in complex with intact TIR substrates. After the first round of 3D classification, 3D auto-refinement using all of the particles in the best class generated a 3.3 Å map. Further 3D classifications focusing on either two ZnB plus flanking DNA regions or on one ZnB domain with symmetry expansion were used to obtain the final 3.4 Å map or a 3.5 Å map with clear ZnB domain density. All three maps were used for cross-references in model building. The final map and accompanying local resolution illustrations are enclosed in the dashed black box.



Extended Data Fig. 2. Single-particle cryo-EM analysis of HzTransib in complex with nicked TIR substrates.

a. Flow chart of cryo-EM image processing for HzTransib PRC with nicked TIR substrates. After the first round of 3D classification with two MBP regions masked, 3D auto-refinement using all of the particles in the best class generated a 3.2 Å map. Further 3D classifications focusing on either two ZnB plus flanking DNA regions or on one ZnB domain with symmetry expansion were used to obtain the final 3.3 Å map or a 3.4 Å map with clear ZnB domain density. All three maps were used for cross-references in model building. **b.** Flow


chart of cryo-EM image processing for HzTransib HFC with nicked TIR substrates. After initial 3D auto-refinement, particles in the over-represented 2D classes were manually adjusted to alleviate the preferred particle orientation problem. Subsequent 3D classification and auto-refinement yielded a 4.6 Å map with even angular distribution. The final maps and accompanying local resolution illustrations are enclosed in the dashed black box.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




Extended Data Fig. 3. Single-particle cryo-EM analysis of HzTransib in complex with TIR substrates in reaction conditions that support catalysis.

Flow chart for HzTransib TEC and STC map reconstructions from HzTransib-intact TIR DNA complex prepared at 30°C in the presence of Mg²⁺. Different subsets of particle images were selected from different classification schemes to produce three refined cryo-EM maps: final STC map at 3.3 Å, final TEC map at 4.2 Å and a 4.5 Å map encompassing one HzTransib and TIR protomer in TEC with clear ZnB domain density. The two TEC maps were used for cross-references in model building. The final STC and TEC maps and accompanying local resolution illustrations are enclosed in the dashed black box.




Extended Data Fig. 4. Validation of cryo-EM structural models.

a. Half-map FSC and model-map FSC curves of five cryo-EM maps from this study are generated from MolProbtity. Gold-standard FSC curves between the two half maps with indicated resolution at FSC = 0.143 are in blue. FSC curves between the atomic model and the final map with indicated resolution at FSC = 0.5 are in orange. **b.** Cryo-EM densities superimposed with the atomic model for representative regions of HzTransib and TIR complexes.



Extended Data Fig. 5. Structural comparison of HzTransib with RAG1.


a. Superimposition of individual domains from HzTransib and RAG1 structures. Because the ZnC_2 portion of the ZnB domain is missing from the HzTransib Apo structure, ZnB domain from HzTransib STC was used for structural superimposition. Three structural motifs in RAG1 that are responsible for RAG2 interactions are highlighted in red boxes. **b.** The front and top views of HzTransib and RAG1 dimer superimposed by their DDBD domains. **c.** Front and top view of the apo RAG1-RAG2 heterotetramer structure (PDB 4WWX)⁸.



Extended Data Fig. 6. TIR recognition in HzTransib PRC, HFC and TEC.

a, Superimposition of HzTransib dimer in PRC (dark colors) and apo (pale colors) structures by their DDBD illustrates the large conformational changes of ZnB domains (green in one subunit). **b–e**, TIR recognition in HzTransib PRC. **b**, Interactions between HzTransib CTT and the heptamer. Hydrogen bonds are shown as gray dotted lines. Labels for nucleotide residues are italic. **c**, Interactions between HzTransib and last three base pairs of heptamer. **d**, Interactions between HzTransib and transposon end DNA downstream of heptamer. **e**, Active site of HzTransib PRC structure. Distances between Mg^{2+} ion and scissile phosphate or E435 are indicated. **f**, The front and top views of two HzTransib PRC structures (incubated with either intact or nicked TIRs at 4°C) superimposed by their DDBD domains. The HzTransib nicked PRC complex is referred to as a PRC because of its strong structural resemblance to the intact DNA PRC. Depending on reaction conditions (temperature and divalent cation; see Methods), the nicked TIR substrate can be incorporated into either a nicked PRC or the HFC. **g**, Superimposition of HzTransib dimer in HFC and PRC structures by their DDBD shows the inward movements of ZnB domains and dimer closure. **h–k**, TIR


recognition in HzTransib HFC. **h**, Interactions between HzTransib and the first three base pairs of heptamer. **i**, The first nucleotide of the heptamer (C1) is flipped out and buried in a pocket. **j**, Interactions between HzTransib $\alpha 9$ - $\alpha 10$ loop and TIR at heptamer-flanking DNA junction. **k**, Active site of HzTransib HFC structure. **l**, Interactions between HzTransib and TIR flanking DNA in PRC. **m**, Interactions between HzTransib ZnB domain and TIR flanking DNA in HFC. **n**, Superimposition of HzTransib dimer in TEC and HFC structures by their DDBD shows the outward movements of ZnB domains. **o**, Comparison of transposon end DNA in TEC to that in HFC or in PRC. Mg^{2+} and Ca^{2+} ions are green and slate gray, respectively; other structure elements are colored as in Fig. 2b. Scissile phosphate in each structure is highlighted in yellow.



Extended Data Fig. 7. Validation and analysis of HzTransib STC structure.

a, Superimposition of 5 bp TSD region with the cryo-EM map contoured at 5.5 σ . **b**, Front and top views of HzTransib STC structure superimposed with HzTransib HFC structure. **c**, Comparison of target DNA from HzTransib, retrovirus integrases, Mos1 transposase and Mu transposase STC structures. Target site DNAs are shown as green and red. The approximate degree of bending in each target DNA is indicated. HzTransib is the only DDE/D-family transposase/integrase for which a STC structure has been reported that lacks a bend or base unpairing at the center of the target site DNA. Instead, HzTransib strongly bends target DNA

near both edges of the target site DNA (between position -2 and -1, and position 1 and 2), leading to a total ~ 150° directional change of target DNA. Target DNAs in retroviral integrase STC structures exhibit relatively mild bends with one backbone kink at the center of target site DNA, regardless of its length (ranging from 4 bp in PFV integrase to 6 bp in RSV integrase). The sharp bending (~ 150°) at the center of the Mos1 target DNA is achieved by flipping of the adenines in the TA target site. The target DNA in Mu STC exhibits a more continuous bending pattern through the 5 bp target site DNA, with one bend before the target site (between position -3 and -2), one at the center, and one immediately after the target site DNA (between position 2 and 3). The central bend is facilitated by the T·T mismatch in the target site. **d**, Transposon end-target DNA junction region of the HzTransib STC model superimposed with cryo-EM map contoured at 5.5 σ . Nucleotide residues in target DNA are labeled with a "T" subscript. **e**, Difference density between the HzTransib STC cryo-EM map and the model showing the uncleaved target DNA phosphodiester bond in a portion of the particles used for cryo-EM map reconstruction. The difference map was contoured at 6 σ . **f**, Superimposition of HzTransib TCC (protein in orange and metal ions in green) active site with HzTransib HFC active site (protein in purple and metal ions in gray). Distances are in Å. Attacking oxygen atoms in HFC and TCC are highlighted in black and red circles, respectively. In TCC, the phosphorus is 2.4 Å from the attacking oxygen and the two metal ions are 3.2 Å apart. These distances are 3.6 Å and 4.2 Å in HFC. **g**, Sequence alignment of Transib transposases, vertebrate RAG1 and deuterostome invertebrate RAG1L proteins, showing the regions corresponding to three RAG2-binding interfaces in RAG1. Residue numbers are for HzTransib. Species name abbreviations used in this paper: Hs, *Homo sapiens* (human); Mm, *Mus musculus* (mouse); Dr, *Danio rerio* (zebrafish); Gg, *Gallus gallus* (chicken); Bb, *Branchiostoma belcheri* (amphioxus); Sp, *Strongylocentrotus purpuratus* (purple sea urchin); Pf, *Ptychodera flava* (acorn worm); Pm, *Petromyzon marinus* (sea lamprey); Af, *Asterias forbesi* (sea star).



Extended Data Fig. 8. Structural insights into the function and evolution of HzTransib CTT.

a, Interactions between HzTransib CTT α20 and ZnB domain α12-α13. Residues in CTT and ZnB are colored red and green, respectively. Residues involved in hydrophobic interactions are shown as ball-and-stick. **b**, Superimposition of ZnB domain (pale colors) together with CTT α20 (dark colors) from the structures representing five steps in transposition. **c**, Cleavage of DNA substrates bearing a 5’TIR/3’TIR pair by MBP-tagged wild-type or CTT truncated mutant HzTransib transposases, each with N-terminal 16 amino acids removed. The DNA cleavage products were resolved on a 6% Tris-borate-EDTA (TBE) polyacrylamide gel and stained with SYBR Gold. Open and closed arrowheads indicate single 5’TIR and single 3’TIR cleavage products, respectively. Red asterisk marks the double cleavage band. The experiment was repeated at least three times independently and similar results were obtained. For gel source data, see Supplementary Figure 1. **d**, Superimposition of HzTransib, RAG1 and BbRAG1L structures by the first two helices of

their CTDs. HzTransib and BbRAG1L CTT extend from the structurally conserved CTD and point in different directions.

e, Sequence alignment of HzTransib CTT with vertebrate RAG1 CTT and deuterostome invertebrate RAG1L CTT showing highly divergent sequences among the three groups. Residues mediating the hydrophobic interactions between ZnB α 12– α 13 and CTT α 20 are highlighted in green. Residue numbers and secondary structure elements at the top of the sequence alignment are for HzTransib. The residue number for the final aa in the sequence alignment is indicated for selected sequences.

Extended Data Table 1

Statistics of crystal data collection, phasing and refinement

	HzTransib apo native (PDB 6PQN)	HzTransib apo Br derivative	HzTransib apo I derivative	HzTransib apo Os derivative	HzTransib apo Pt derivative	HzTransib apo Hg derivative
Data collection						
Space group	P6 ₁ 22	P6 ₁ 22	P6 ₁ 22	P6 ₁ 22	P6 ₁ 22	P6 ₁ 22
Cell dimensions						
<i>a</i> , <i>b</i> , <i>c</i> (Å)	160.292, 160.292, 235.858	159.315, 159.315, 236.805	159.797, 159.797, 238.293	160.238, 160.238, 235.817	160.912, 160.912, 236.643	160.353, 160.353, 236.264
α , β , γ (°)	90, 90, 120	90, 90, 120	90, 90, 120	90, 90, 120	90, 90, 120	90, 90, 120
Resolution (Å)	200.0–3.01 (3.19–3.01)*	200.0–3.84 (4.30–3.84)	200.0–3.81 (4.17–3.81)	200.0–3.18 (3.35–3.18)	200.0–3.96 (4.42–3.96)	200.0–3.14 (3.31–3.14)
R_{sym} or R_{merge}	0.086 (1.829)	0.280 (3.748)	0.196 (3.157)	0.135 (3.403)	0.141 (2.482)	0.134 (3.983)
$I/\sigma I$	14.47 (0.75)	21.46 (0.9)	19.87 (1.2)	21.18 (0.9)	22.45 (1.1)	21.4 (0.9)
Completeness (%)	99.3 (99.3)	99.7 (99.1)	100.0 (99.8)	100.0 (100.0)	99.7 (99.1)	99.8 (99.0)
Redundancy	7.7 (7.6)	12.7 (12.7)	19.2(19.9)	19.3 (19.1)	12.7 (13.3)	19.5 (20.0)
Refinement						
Resolution (Å)	80.15–3.01 (3.117–3.01)					
No. reflections	35894 (3455)					
R_{work} / R_{free}	0.220/0.277					
No. atoms						
Protein	7288					
Ligand/ion	83					
Water	28					
<i>B</i> -factors						
Protein	147.85					
Ligand/ion	183.99					
Water	108.59					
R.m.s deviations						
Bond lengths (Å)	0.004					

	HzTransib apo native (PDB 6PQN)	HzTransib apo Br derivative	HzTransib apo I derivative	HzTransib apo Os derivative	HzTransib apo Pt derivative	HzTransib apo Hg derivative
Bond angles (°)	0.77					

* One crystal was used for each dataset.

* Values in parentheses are for highest-resolution shell.

Extended Data Table 2

Statistics of cryo-EM data collection, refinement and validation

	PRC (intact TIR) (EMD-20452) (PDB 6PQR)	PRC (nicked TIR) (EMD-20453) (PDB 6PQU)	HFC (EMD-20455) (PDB 6PQX)	TEC (EMD-20456) (PDB 6PQY)	STC (EMD-20457) (PDB 6PR5)
Data collection and processing					
Magnification	130,000	130,000	130,000	130,000	130,000
Voltage (kV)	300	300	300	300	300
Electron exposure (e ⁻ /Å ²)	50.8	52.2	52.2	54.4	54.4
Defocus range (µm)	-1.5—2.5	-1.5—2.5	-1.5—2.5	-1.5—2.5	-1.5—2.5
Pixel size (Å)	1.05	1.05	1.05	1.05	1.05
Symmetry imposed	C2	C2	C2	C2	C1
Initial particle images (no.)	243,518	300,406	262,691	228,413	228,413
Final particle images (no.)	32,984	59,333	3,997	26,397	43,661
Map resolution (Å)	3.4	3.3	4.6	4.2	3.3
FSC threshold	0.143	0.143	0.143	0.143	0.143
Map resolution range (Å)	2.4—5.2	2.4—5.6	4.0—8.0	3.7—6.8	2.5—5.6
Refinement					
Initial model used (PDB code)	6PQN	6PQN	6PQN	6PQN	6PQN
Model resolution (Å)	3.7	3.6	4.8	4.7	3.5
FSC threshold	0.5	0.5	0.5	0.5	0.5
Model resolution range (Å)	2.4—5.2	2.4—5.6	4.0—8.0	3.7—6.8	2.5—5.6
Map sharpening <i>B</i> factor (Å ²)	-90	-90	-126	-120	-90
Model composition					
Non-hydrogen atoms	9266	10004	10116	8690	10194
Protein residues	936	936	960	920	960
Nucleotides	88	124	120	64	124
Ligands	6	6	4	0	6
<i>B</i> factors (Å²)					
Protein	105.51	74.58	89.52	182.34	59.68

	PRC (intact TIR) (EMD-20452) (PDB 6PQR)	PRC (nicked TIR) (EMD-20453) (PDB 6PQU)	HFC (EMD-20455) (PDB 6PQX)	TEC (EMD-20456) (PDB 6PQY)	STC (EMD-20457) (PDB 6PR5)
Nucleic acid	104.92	131.57	160.90	158.19	91.35
Ligand	109.58	93.13	81.45		69.54
R.m.s. deviations					
Bond lengths (Å)	0.009	0.008	0.006	0.007	0.008
Bond angles (°)	0.830	0.890	0.984	0.980	0.768
Validation					
MolProbity score	1.91	2.04	2.39	2.35	1.64
Clashscore	16.01	23.12	16.06	24.55	13.64
Poor rotamers (%)	0.24	1.21	2.35	0.49	0.71
Ramachandran plot					
Favored (%)	96.74	97.39	94.14	92.51	98.33
Allowed (%)	3.26	2.39	5.23	6.83	1.36
Disallowed (%)	0	0.22	0.63	0.66	0.31

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank W. Eliason for assistance with size-exclusion chromatography-multiple angle light scattering; K. Zhou for assistance in freezing the cryo-EM grids of HzTransib-intact TIR complex; S. Wu for help with cryo-EM data collection at Yale West Campus; the staff of the Advanced Photon Source beamlines 24-ID-C and 24-ID-E for technical assistance with X-ray crystallography data collection; N. Craig for critical reading of and many helpful comments on the manuscript. We are particularly grateful for Dr. Thomas Steitz's advice, mentoring, and support during the early phases of this work; this paper is dedicated to his memory. This work was supported by NIH grant R01 AI137079 (D.G.S.), Yale University School of Medicine James Hudson Brown-Alexander Brown Coxé Postdoctoral Fellowship (C.L.), and NVIDIA GPU Grant Program (C.L. and Y.Y.).

References

1. Feschotte C & Pritham EJ DNA transposons and the evolution of eukaryotic genomes. *Annu. Rev. Genet* 41, 331–368, (2007). [PubMed: 18076328]
2. Carmona LM & Schatz DG New insights into the evolutionary origins of the recombination-activating gene proteins and V(D)J recombination. *FEBS J* 284, 1590–1605, (2017). [PubMed: 27973733]
3. Gellert M V(D)J recombination: RAG proteins, repair factors, and regulation. *Annu. Rev. Biochem* 71, 101–132, (2002). [PubMed: 12045092]
4. Chen S & Li X Molecular characterization of the first intact Transib transposon from *Helicoverpa zea*. *Gene* 408, 51–63, (2008). [PubMed: 18031956]
5. Hencken CG, Li X & Craig NL Functional characterization of an active Rag-like transposase. *Nat. Struct. Mol. Biol* 19, 834–836, (2012). [PubMed: 22773102]
6. Craig NL A Moveable Feast: An Introduction to Mobile DNA in *Mobile DNA III* (eds Craig NL et al.) 3–39 (ASM Press, 2015).

7. Montano SP & Rice PA Moving DNA around: DNA transposition and retroviral integration. *Curr. Opin. Struct. Biol* 21, 370–378, (2011). [PubMed: 21439812]
8. Kim MS, Lapkouski M, Yang W & Gellert M Crystal structure of the V(D)J recombinase RAG1-RAG2. *Nature* 518, 507–511, (2015). [PubMed: 25707801]
9. Schatz DG & Swanson PC V(D)J recombination: mechanisms of initiation. *Annu. Rev. Genet* 45, 167–202, (2011). [PubMed: 21854230]
10. Kapitonov VV & Jurka J RAG1 core and V(D)J recombination signal sequences were derived from Transib transposons. *PLoS Biol* 3, e181, (2005). [PubMed: 15898832]
11. Zhou L et al. Transposition of hAT elements links transposable elements and V(D)J recombination. *Nature* 432, 995–1001, (2004). [PubMed: 15616554]
12. Hickman AB et al. Structural basis of hAT transposon end recognition by Hermes, an octameric DNA transposase from *Musca domestica*. *Cell* 158, 353–367, (2014). [PubMed: 25036632]
13. Agrawal A, Eastman QM & Schatz DG Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. *Nature* 394, 744–751, (1998). [PubMed: 9723614]
14. Hiom K, Melek M & Gellert M DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. *Cell* 94, 463–470, (1998). [PubMed: 9727489]
15. Ru H et al. Molecular Mechanism of V(D)J Recombination from Synaptic RAG1-RAG2 Complex Structures. *Cell* 163, 1138–1152, (2015). [PubMed: 26548953]
16. Kim MS et al. Cracking the DNA Code for V(D)J Recombination. *Mol. Cell* 70, 358–370 e354, (2018). [PubMed: 29628308]
17. Ru H et al. DNA melting initiates the RAG catalytic pathway. *Nat. Struct. Mol. Biol* 25, 732–742, (2018). [PubMed: 30061602]
18. Montano SP, Pigli YZ & Rice PA The mu transpososome structure sheds light on DDE recombinase evolution. *Nature* 491, 413–417, (2012). [PubMed: 23135398]
19. Maertens GN, Hare S & Cherepanov P The mechanism of retroviral integration from X-ray structures of its key intermediates. *Nature* 468, 326–329, (2010). [PubMed: 21068843]
20. Yin Z et al. Crystal structure of the Rous sarcoma virus intasome. *Nature* 530, 362–366, (2016). [PubMed: 26887497]
21. Ballandras-Colas A et al. A supramolecular assembly mediates lentiviral DNA integration. *Science* 355, 93–95, (2017). [PubMed: 28059770]
22. Passos DO et al. Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome. *Science* 355, 89–92, (2017). [PubMed: 28059769]
23. Richardson JM, Colloms SD, Finnegan DJ & Walkinshaw MD Molecular architecture of the Mos1 paired-end complex: the structural basis of DNA transposition in a eukaryote. *Cell* 138, 1096–1108, (2009). [PubMed: 19766564]
24. Morris ER, Grey H, McKenzie G, Jones AC & Richardson JM A bend, flip and trap mechanism for transposon integration. *eLife* 5, (2016).
25. Dawson A & Finnegan DJ Excision of the *Drosophila* mariner transposon Mos1. Comparison with bacterial transposition and V(D)J recombination. *Mol. Cell* 11, 225–235, (2003). [PubMed: 12535535]
26. Carmona LM, Fugmann SD & Schatz DG Collaboration of RAG2 with RAG1-like proteins during the evolution of V(D)J recombination. *Genes Dev* 30, 909–917, (2016). [PubMed: 27056670]
27. Davies DR, Goryshin IY, Reznikoff WS & Rayment I Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. *Science* 289, 77–85, (2000). [PubMed: 10884228]
28. Lankas F, Sponer J, Langowski J & Cheatham TE 3rd. DNA basepair step deformability inferred from molecular dynamics simulations. *Biophys. J* 85, 2872–2883, (2003). [PubMed: 14581192]
29. Yuan YW & Wessler SR The catalytic domain of all eukaryotic cut-and-paste transposase superfamilies. *Proc. Natl. Acad. Sci. USA* 108, 7884–7889, (2011). [PubMed: 21518873]
30. Hickman AB et al. Structural insights into the mechanism of double strand break formation by Hermes, a hAT family eukaryotic DNA transposase. *Nucl. Acids Res* 46, 10286–10301, (2018). [PubMed: 30239795]

31. Yang W, Lee JY & Nowotny M Making and breaking nucleic acids: two-Mg²⁺-ion catalysis and substrate specificity. *Mol. Cell* 22, 5–13, (2006). [PubMed: 16600865]
32. Huang S et al. Discovery of an Active RAG Transposon Illuminates the Origins of V(D)J Recombination. *Cell* 166, 102–114, (2016). [PubMed: 27293192]
33. Zhang Y et al. Transposon molecular domestication and the evolution of the RAG recombinase. *Nature* 569, 79–84, (2019). [PubMed: 30971819]
34. Hare S, Gupta SS, Valkov E, Engelman A & Cherepanov P Retroviral intasome assembly and inhibition of DNA strand transfer. *Nature* 464, 232–236, (2010). [PubMed: 20118915]
35. Tsai CL, Chatterji M & Schatz DG DNA mismatches and GC-rich motifs target transposition by the RAG1/RAG2 transposase. *Nucl. Acids Res* 31, 6180–6190, (2003). [PubMed: 14576304]
36. Lee GS, Neiditch MB, Sinden RR & Roth DB Targeted transposition by the V(D)J recombinase. *Mol. Cell Biol* 22, 2068–2077, (2002). [PubMed: 11884595]
37. Kabsch W Xds. *Acta Crystallogr. D Biol. Crystallogr* 66, 125–132, (2010). [PubMed: 20124692]
38. Sheldrick GM A short history of SHELX. *Acta Crystallogr A* 64, 112–122, (2008). [PubMed: 18156677]
39. Terwilliger TC et al. Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. *Acta Crystallogr D Biol Crystallogr* 65, 582–601, (2009). [PubMed: 19465773]
40. Terwilliger TC et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta Crystallogr D Biol Crystallogr* 64, 61–69, (2008). [PubMed: 18094468]
41. Emsley P, Lohkamp B, Scott WG & Cowtan K Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr* 66, 486–501, (2010). [PubMed: 20383002]
42. Adams PD et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr* 66, 213–221, (2010). [PubMed: 20124702]
43. Chen VB et al. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr. D Biol. Crystallogr* 66, 12–21, (2010). [PubMed: 20057044]
44. Zheng SQ et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* 14, 331–332, (2017). [PubMed: 28250466]
45. Rohou A & Grigorieff N CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *J Struct Biol* 192, 216–221, (2015). [PubMed: 26278980]
46. Zivanov J et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* 7, (2018).
47. Bai XC, Rajendra E, Yang G, Shi Y & Scheres SH Sampling the conformational space of the catalytic subunit of human gamma-secretase. *Elife* 4, (2015).
48. Kucukelbir A, Sigworth FJ & Tagare HD Quantifying the local resolution of cryo-EM density maps. *Nat. Methods* 11, 63–65, (2014). [PubMed: 24213166]
49. Pettersen EF et al. UCSF Chimera--a visualization system for exploratory research and analysis. *J. Comput. Chem* 25, 1605–1612, (2004). [PubMed: 15264254]
50. Goddard TD et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci* 27, 14–25, (2018). [PubMed: 28710774]
51. Sievers F & Higgins DG Clustal omega. *Curr Protoc Bioinformatics* 48, 3 13 11–16, (2014). [PubMed: 25501943]
52. Robert X & Gouet P Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res* 42, W320–324, (2014). [PubMed: 24753421]
53. Wu X & Bartel DP kpLogo: positional k-mer analysis reveals hidden specificity in biological sequences. *Nucl. Acids Res* 45, W534–W538, (2017). [PubMed: 28460012]




Figure 1. Functional and structural overview of HzTransib.

a, Schematic of DNA recombination and transposition pathways of RAG and HzTransib. RSS or TIR are shown as triangles with wide side indicating heptamer sequence. TSD, target site duplication. **b**, Sequence and numbering of the HzTransib TIR substrate. Heptamer and nonamer sequences of TIR and RSS are shown in red. TS, transferred strand. NTS, non-transferred strand. The nicking site on HzTransib TIR is between T-1 and C1 on NTS. **c**, Domain organization of HzTransib in comparison with mouse RAG1. Domain boundaries are shown by residue number. Active site carboxylates are labeled in red. **d**, Front and top view of the apo HzTransib dimer crystal structure.




Figure 2. Structures of HzTransib-TIR complexes during transposon binding and excision.
a, Overall cryo-EM structure of HzTransib PRC with intact TIR substrates. Two HzTransib subunits are colored in orange and purple. **b**, *Trans* architecture of HzTransib-TIR complex. DDBD and CTD from *trans* HzTransib are in pale colors. Mg^{2+} ion, green sphere; catalytic carboxylates, red sticks; scissile phosphate is highlighted in yellow. **c**, Overall cryo-EM structure of HzTransib HFC with nicked TIR substrates. **d**, Comparison of TIR substrates from PRC and HFC. **e**, Overall cryo-EM structure of HzTransib TEC with catalytically cleaved transposon end DNAs. **f**, Transposon end nucleotides are stabilized by ZnB domain residues, but the 3'-OH is not coordinated for the subsequent strand transfer reaction.




Figure 3. Transposon end integration and strand transfer complex.

a, Schematic of strand transfer product. Heptamer and target site sequences are colored red and green, respectively. **b**, Overall cryo-EM structure of HzTransib in complex with naturally generated strand transfer product. **c**, Different conformations of $\alpha 9$ - $\alpha 10$ target site binding loop in STC and HFC. **d**, Interactions between $\alpha 9$ - $\alpha 10$ loop and 5 bp target site. Hydrogen bonds are shown as dashed lines. **e**, Sequence logo representing nucleotide frequencies at HzTransib TIRs integration sites. **f**, Active site of the TCC model. Mg²⁺ ions, green spheres. Nucleotide residues in target DNA are indicated with “T” subscript. **g**, Sequence alignment of Transib transposases, vertebrate RAG1 and deuterostome invertebrate RAG1L proteins. Residue numbers and secondary structure annotation are for HzTransib. The $\alpha 9$ - $\alpha 10$ loop in HzTransib is highlighted in green. Species name abbreviations are defined in the legend of Extended Data Fig. 7g.




Figure 4. HzTransib CTT conformational changes during transposition.

a, b, Side-by-side comparison of five HzTransib structures, with ZnB and CTT domains colored in green and red, respectively.